Researchers suggest that temporal ultrasound may be an appealing choice for monitoring disease activity in patients with cranial giant cell arteritis treated with tocilizumab.
Researchers studied the risk factors for relapse, including prednisolone clearance and glucocorticoid-induced transcript 1 promoter polymorphism (rs37972), in patients with giant cell arteritis.
Researchers evaluated the influence of disease-related findings and treatment outcomes on survival in a population-based cohort of patients with giant cell arteritis.
The use of color duplex sonography for the diagnosis of patients with suspected giant cell arteritis is associated with high specificity and positive predictive value.
The utility of PET and CT imaging to complement temporal artery biopsy in patients with newly diagnosed giant cell arteritis who are receiving glucocorticoid therapy remains equivocal.
Actemra (tocilizumab) has been FDA-approved for its use in giant cell arteritis treatment.
FDA will fast track review of nonsteroidal treatment option for giant cell arteritis.
Patients experienced an elevated risk of venous thromboembolism both immediately before and immediately after giant cell arteritis diagnosis.
Treatment of giant cell arteritis or granulomatosis with polyangiitis with prednisolone or prednisone has been linked to elevated risks of type 2 diabetes early during treatment.
Tocilizumab (Actemra®,Genentech) is the first treatment proposed for giant cell arthritis in 50 years.
